Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

DE NOVO POST-DIAGNOSIS VITAMIN D USE AND BREAST CANCER MORTALITY

6th International Conference on EPIDEMIOLOGY & PUBLIC HEALTH

Jamie Madden, Kathleen Bennett, Laura Murphy, Ian Barron and Lina Zgaga

RCSI, Ireland Health Research Board, Ireland Johns Hopkins Baltimore, USA Trinity College, Ireland

Posters & Accepted Abstracts: Epidemiology (Sunnyvale)

DOI: 10.4172/2161-1165-C1-018

Abstract
Introduction: Experimental data suggests a protective effect of vitamin D on breast cancer progression but epidemiological evidence is emerging. A recent meta-analysis however suggested a large reduction in breast cancer mortality (HR: 0.65; 95% CI: 0.44-0.98)) in those in the highest quartile of circulating 25(OH) D levels compared to the lowest quartile when measured at diagnosis. Aim and Methods: In this study we investigate, in a large linked national cancer registry and prescribing database in Ireland, associations between vitamin D use initiated after a diagnosis (de novo) in women with stage I-III breast cancer and all-cause and breast cancer- specific mortality (n=5417); see Figure 1. Initiation of vitamin D post-diagnosis was identified from the linked national prescription data (n=2570 (48%) initiating vitamin D). Multivariate cox proportional hazards models were used to estimate hazard ratios (HRs) for associations between de novo vitamin D use and mortality while adjusting for patient, tumour characteristics and treatment. Results: Initiation of vitamin D was significantly higher among those in receipt of statin, bisphosphonate and anti-estrogen therapy. Those with a perceived better prognosis also had a higher initiation rate (e.g. ER/PR positive and HER2 negative). After appropriate adjustment for confounders, there was a significant association between de novo vitamin D use post-diagnosis (yes/no time-varying) and, breast cancer-specific (HR: 0.69; 95% CI: 0.55-0.86) and all-cause mortality (HR: 0.76; 95% CI: 0.65-0.90). After additional analysis correcting for imbalance between treatment groups using propensity score analysis, a significant association persisted between vitamin D use post-diagnosis and breast cancer-specific mortality (HR: 0.70; 95% CI: 0.52-0.93), but not for all-cause mortality (HR: 0.82; 95% CI: 0.67-1.01). Conclusion: Breast cancer-specific mortality in de novo vitamin D users post-diagnosis was significantly lower than nonusers. Vitamin D has the potential as a non-toxic treatment to improve survival in breast cancer patients.
Biography
Top